Form 4: Aptevo Therapeutics Executive Lamothe Reports Stock Transactions

Sentiment:

SEC Form 4


Jeffrey G. Lamothe, EVP and COO of Aptevo Therapeutics, reports the conversion of Restricted Stock Units (RSUs) into common stock.

Summary

  • Jeffrey G. Lamothe, EVP and COO of Aptevo Therapeutics Inc., filed a Form 4 on August 9, 2024, reporting transactions involving the company's stock.
  • On August 8, 2024, Lamothe converted 42 Restricted Stock Units (RSUs) into 42 shares of common stock.
  • Additionally, Lamothe converted 272 RSUs into 272 shares of common stock on the same day.
  • These RSUs were granted on August 9, 2022, and vested in installments beginning August 8, 2023.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive, and it doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Stakeholder Impact

  • The transactions may have a minor dilutive effect on existing shareholders due to the issuance of new shares upon RSU conversion.

Key Dates

DateDescription
08/09/2022Reporting person was granted 5,500 (125 post-split) RSUs, vesting in three approximately equal annual installments beginning on August 8, 2023.
08/09/2022Reporting person was granted 23,958 (544 post-split) RSUs, vesting in two approximately equal annual installments beginning on August 8, 2023.
08/08/2023Beginning of vesting period for RSUs granted on August 9, 2022.
08/08/2024Lamothe converted 42 and 272 RSUs into common stock.
08/09/2024Date of Form 4 filing.

Keywords

Aptevo Therapeutics, APVO, Form 4, Jeffrey G. Lamothe, Restricted Stock Units, RSUs, Stock Transaction, EVP, COO

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.